---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-088621"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:38:31.181664+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Organon Q2 2023 revenue $1.61B (+4% ex-FX); adj. EPS $1.31; FY guidance narrowed

## Summary
- GAAP diluted EPS $0.95; non-GAAP adjusted diluted EPS $1.31 vs $1.25 prior year.
- Women's Health revenue $438M (+10% ex-FX); Nexplanon up 12% ex-FX; fertility +17% ex-FX.
- Biosimilars $135M (+15% ex-FX); Renflexis +20% ex-FX; Hadlima launched in US July 1.
- Established Brands $995M (flat ex-FX); expects flat full-year revenue.
- FY 2023 revenue guidance narrowed to $6.25-6.45B; adj. EBITDA margin 31.5%-33.0%.

## SEC filing metadata
- accession: 0001104659-23-088621
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465923088621/0001104659-23-088621-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465923088621/tm2322580d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-088621
- JSON: https://secwatch.observer/filing/0001104659-23-088621.json
- Plain text: https://secwatch.observer/filing/0001104659-23-088621.txt

## Key facts
- Earnings Releases
  Organon & Co. reported the second quarter ended June 30, 2023 results: revenue $1,608 million, net income $242 million, EPS $0.95. Guidance reaffirmed.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $1,608 million
  - Net income: $242 million
  - EPS: $0.95
  - Guidance: reaffirmed
  - Result: reported results
  source text: Organon Reports Results for the Second Quarter Ended June 30, 2023 • Second quarter 2023 revenue of $1,608 million • Second quarter 2023 diluted earnings per share of $0.95
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821825/000110465923088621/0001104659-23-088621-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.